

Cardiovascular magnetic resonance phenotyping of heart failure with mildly reduced ejection fraction

Louise A. E. Brown ¹, Ali Wahab ¹, Eunice Ikongo¹, Chirstopher E. D. Saunderson¹, Nicholas Jex¹, Sharmaine Thirunavukarasu¹, Amrit Chowdhary¹, Arka Das¹, Thomas P. Craven¹, Eylem Levelt¹, Erica Dall'Armellina¹, Kristopher D. Knott², John P. Greenwood¹, James C. Moon², Hui Xue ³, Peter Kellman ³, Sven Plein ¹, and Peter P. Swoboda ¹*

¹Multidisciplinary Cardiovascular Research Centre (MCRC) and Biomedical Imaging Science Department, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Clarendon Way, Leeds LS2 9JT, UK; ²The Cardiovascular Magnetic Resonance Imaging Unit and The Inherited Cardiovascular Diseases Unit, Barts Heart Centre, St Bartholomew's Hospital, West Smithfield, London, UK; and ³National Heart, Lung, and Blood Institute, National Institutes of Health, DHHS, Bethesda, MD, USA

Received 30 November 2021; accepted after revision 14 September 2022; online publish-ahead-of-print 26 October 2022

Aims

The 2016 European Society of Cardiology Heart Failure Guidelines defined a new category: heart failure with mid-range ejection fraction (HFmrEF) of 40–49%. This new category was highlighted as having limited evidence and research was advocated into underlying characteristics, pathophysiology, and diagnosis. We used multi-parametric cardiovascular magnetic resonance (CMR) to define the cardiac phenotype of presumed non-ischaemic HFmrEF.

Methods and results

Patients ($N = 300$, 62.7 ± 13 years, 63% males) with a clinical diagnosis of heart failure with no angina symptoms, history of myocardial infarction, or coronary intervention were prospectively recruited. Patients underwent clinical assessment and CMR including T1 mapping, extracellular volume (ECV) mapping, late gadolinium enhancement, and measurement of myocardial blood flow at rest and maximal hyperaemia. Of 273 patients in the final analysis, 93 (34%) patients were categorized as HFmrEF, 46 (17%) as heart failure with preserved ejection fraction (HFpEF), and 134 (49%) as heart failure with reduced ejection fraction (HFrEF). Nineteen (20%) patients with HFmrEF had evidence of occult ischaemic heart disease. Diffuse fibrosis and hyperaemic myocardial blood flow were similar in HFmrEF and HFpEF, but HFmrEF showed significantly lower native T1 (1311 ± 32 vs. 1340 ± 45 ms, $P < 0.001$), ECV (24.6 ± 3.2 vs. $26.3 \pm 3.1\%$, $P < 0.001$), and higher myocardial perfusion reserve (2.75 ± 0.84 vs. 2.28 ± 0.84 , $P < 0.001$) compared with HFrEF.

Conclusion


Patients with HFmrEF share most phenotypic characteristics with HFpEF, including the degree of microvascular impairment and fibrosis, but have a high prevalence of occult ischaemic heart disease similar to HFrEF. Further work is needed to confirm how the phenotype of HFmrEF responds to medical therapy.

* Corresponding author. Email: p.swoboda@leeds.ac.uk

© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<https://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

Graphical Abstract



Downloaded from https://academic.oup.com/ehj/advance-article/doi/10.1093/ehj/ehj/24/1/38/6774450 by guest on 28 June 2023

There is limited research into the mechanisms of heart failure with mildly reduced ejection fraction (HFmrEF, 40–49%). Using cardiovascular magnetic resonance, we have shown that patients with HFmrEF share most phenotypic characteristics with heart failure with preserved ejection fraction (HFpEF, ≥50%), including the degree of microvascular impairment and fibrosis. However, they also have a high prevalence of occult ischaemic heart disease similar to heart failure with reduced ejection fraction (HFrEF, <40%).

Keywords heart failure • mildly reduced • ejection fraction • cardiovascular magnetic resonance • HFmrEF

Introduction

Heart failure (HF) has historically been classified based on left-ventricular (LV) ejection fraction (EF) and divided into two groups:

HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF). The 2016 European Society of Cardiology (ESC) Heart Failure Guidelines defined a new, middle, category: HF with mid-range ejection fraction (HFmrEF) of 40–49% between

HFrEF (EF \leq 40%) and HFpEF (EF \geq 50%),¹ recently renamed as HF with mildly reduced ejection fraction.²

Heart failure with rEF and HFpEF have been shown to have different patient characteristics, outcomes, and therapeutic response.^{3,4} Within clinical trials, the HFmrEF group has often been excluded, split, or grouped with HFpEF.^{4,5} The 2016 ESC guidelines highlighted this new category as an area with a gap in evidence and advocate research into underlying characteristics, pathophysiology, and diagnosis.

The categorical classification of HF based solely on LVEF has been challenged reflecting overlap in epidemiology, pathophysiology, and clinical manifestation across the defined groups. Large epidemiological registries have shown HFmrEF to most closely resemble HFrEF in terms of age and sex distribution and presence of ischaemic heart disease (IHD), but with less ventricular and atrial dilatation.^{6–8}

Cardiovascular magnetic resonance (CMR) can identify high risk features in HF such as inducible ischaemia, ischaemic scar, focal, and diffuse fibrosis. These characteristics have not previously been described for HFmrEF. However, across the HF spectrum, they have been shown to be potential markers of prognosis and may be helpful in guiding therapy.

We used CMR to define the cardiac phenotype of presumed non-ischaemic HFmrEF specifically comparing the prevalence of occult IHD and tissue characteristics to HFpEF and HFrEF.

Methods

Study population

Patients seen in cardiology clinics and referred for a CMR scan following a clinical diagnosis of HF were prospectively recruited ($N = 300$). Patients were excluded if they had a known history of coronary artery disease (stenosis $>70\%$ on angiography, myocardial infarction, previous percutaneous coronary intervention, or coronary artery bypass grafting) or symptoms of angina. Other exclusion criteria included hypertrophic cardiomyopathy, amyloidosis, congenital heart disease, advanced renal failure, or contraindication to CMR or gadolinium-based contrast agents

Patient characteristics

Patients underwent clinical assessment on the day of their CMR appointment, including medical history, New York Heart Association (NYHA) function class, risk factors, and medical management. In patients with an LVEF $\geq 50\%$, an H2FPEF score⁹ was calculated using previous echocardiogram results, where available, and medical history. Where the H2FPEF score indicated that a diagnosis of HFpEF was unlikely (score < 2), these patients were excluded from further analysis. Haematocrit (Hct) was measured from a blood sample taken at the time of the CMR scan.

Study protocol

All CMR studies were undertaken on a 3T system (Siemens Magnetom Prisma, Erlangen, Germany). Participants were advised to avoid caffeine for 24 h before the study. The protocol (Figure 1) consisted of cine imaging, native, and post-contrast T1 mapping using a Modified Look Locker Inversion recovery (MOLLI) sequence, stress and rest perfusion using free breathing, motion corrected (MOCO) automated in-line perfusion mapping,¹⁰ and MOCO bright blood late gadolinium enhancement (LGE). T1 and perfusion maps were acquired as three short axis, 8 mm slices, at basal, mid, and apical levels, with slice spacing varied on a per patient basis to cover the left ventricle. LGE images were acquired as a short-axis stack and in four-, three-, and two-chamber views. When it was unclear if enhancement seen on bright blood LGE was ischaemic, a dark blood LGE stack was also acquired.¹¹ A full protocol is available in [Supplementary data online, Supplement 1](#).

For perfusion imaging, adenosine was infused for a minimum of 3 min, at a rate of 140 $\mu\text{g}/\text{kg}/\text{min}$ and increased up to a maximum of 210 $\mu\text{g}/\text{kg}/\text{min}$ if

there was insufficient haemodynamic response (heart rate increase < 10 b.p.m.) or there was no symptomatic response. Images were acquired over 90 dynamics to allow for poor ventricular function. A 10 min interval was kept between perfusion acquisitions. An intravenous bolus of 0.05 mmol/kg gadobutrol (Gadovist, Leverkusen, Germany) was administered at 5 mL/s followed by a 20 mL saline flush using an automated injection pump (Medrad MRXperion Injection System, Bayer). Perfusion mapping was performed using the Gadgetron streaming software image reconstruction framework.¹⁰

Qualitative analysis

LGE was reported if enhancement was identified on two orthogonal planes or, where available, on both bright and dark blood LGE images. Ischaemic LGE was defined as involving the subendocardium in a typical coronary distribution. Inducible ischaemia was defined as a visual perfusion defect affecting > 1 segment present at stress but not at rest, or matching infarct on LGE imaging, in a coronary distribution.

Quantitative analysis

T1 and perfusion maps were analysed using cvi42 software (Circle Cardiovascular Imaging, Calgary, Canada). Endocardial and epicardial borders were drawn excluding papillary muscles, right-ventricular insertion points marked, and a 16-segment American Heart Association (AHA) model was used.¹² In order to minimize partial volume effect, a 10% offset was applied to endocardial and epicardial borders. T1 times and myocardial blood flow (MBF) were measured for each of the 16 segments. Where the left-ventricular outflow tract was included, or partial volume effect meant segments were too thin to contour, these segments were excluded from further analysis (184 segments in total; 4%). In order to report global microvascular function (rather than the effects of occult coronary artery disease or replacement fibrosis) segments with ischaemia or late gadolinium enhancement were also excluded from analysis. T1 times and MBF values for all remaining segments were averaged to provide a global value.

Myocardial perfusion reserve (MPR) was calculated as stress:rest MBF. Extracellular volume (ECV) was calculated using the formula 'myocardial ECV = $(1 - \text{Hct}) \times (\Delta R1_{\text{myocardium}} / \Delta R1_{\text{blood}})$ ', where $R1 = 1/T1$ '. These were calculated for each segment and averaged to provide a global value.

Statistical analysis

Analysis was performed using SPSS 23 (IBM SPSS, Armonk, NY, USA). Normality of distribution was assessed using the Shapiro–Wilk test. Data are presented as mean (\pm standard deviation) for continuous data and number (percentage) for categorical data.

Continuous variables were analysed using analysis of variance with *post-hoc* Bonferroni correction to compare groups. Categorical data were analysed using χ^2 test or Fisher's exact test. Correlation was assessed using Pearson r correlation. Statistical tests were two-tailed and $P < 0.05$ was considered significant. Multiple regression analysis was performed to examine the relationship between tissue characteristics and ejection fraction, age, and sex.

This study complies with the Declaration of Helsinki; the locally appointed ethics committee has approved the research protocol (Ref. 17/YH/0300) and informed consent was obtained from all subjects.

Results

Of the 300 patients who were prospectively recruited, a total of 27 were excluded from analysis due to adenosine contraindications ($n = 4$), because data could not be analysed ($n = 4$) or because of exclusion criteria identified after the CMR scan ($n = 19$; Figure 2).

Of the 273 patients included in the final analysis, 134 (49%) met criteria for HFrEF, 93 (34%) had HFmrEF, and 46 (17%) had HFpEF (HFpEF score median 4, interquartile range 3–6).




Figure 1 CMR protocol. At least 10 min was left between stress and rest perfusion acquisitions. Post-contrast T1 mapping was carried out at least 15 min after contrast injection.




Figure 2 Recruitment into study. Three hundred patients were prospectively recruited prior to clinical CMR. About 273 were included in final analysis.

Table 1 Clinical features

	All patients 273	HFpEF 46	HFmrEF 93	HFrEF 134	P-value	HFpEF:HFmrEF	HFmrEF:HFrEF
Age	62.88 ± 12.4	60.39 ± 11.0	61.2 ± 14.3	64.9 ± 12.3	0.022	1.0	0.058
Female, n (%)	104 (36.2)	24 (52.2)	36 (38.7)	34 (25.3)	0.002	0.132	0.032
Hct	43.7 (4.4)	42.6 (4.2)	42.9 (4.1)	44.6 (4.4)	0.003	1.0	0.014
Symptoms							
NYHA 1	183 (63.8)	33 (71.7)	65 (69.9)	75 (56.0)			
2	90 (31.4)	9 (19.6)	24 (25.8)	53 (39.6)	0.051	0.460	0.091
3	14 (4.9)	4 (8.7)	4 (4.3)	6 (4.5)			
SOBOE	106 (36.9)	15 (32.6)	28 (30.0)	60 (44.8)	0.059	0.764	0.026
Orthopnoea	48 (16.7)	7 (15.2)	11 (11.8)	28 (20.9)	0.189	0.575	0.075
Peripheral oedema	45 (15.7)	8 (17.4)	14 (15.0)	22 (16.4)	0.931	0.722	0.782
Risk factors							
Diabetes	52 (18.1)	4 (8.7)	16 (17.2)	29 (21.6)	0.139	0.179	0.410
Hypertension	122 (42.5)	18 (39.1)	40 (43.0)	60 (44.8)	0.800	0.662	0.792
Hypercholesterolaemia	72 (25.1)	9 (19.6)	29 (31.2)	31 (23.1)	0.242	0.148	0.176
Stroke/TIA	38 (13.2)	4 (8.7)	8 (8.6)	23 (17.2)	0.108	0.985	0.065
AF	112 (39)	15 (32.6)	40 (43.0)	57 (42.5)	0.444	0.238	0.943
Smoking history	159 (55.4)	23 (50.0)	52 (55.9)	77 (57.4)	0.678	0.510	0.817
BMI (kg/m ²)	27.96 ± 4.94	28.7 ± 5.30	28.1 ± 4.9	27.6 ± 4.9	0.420	1.000	1.000
Medications							
Antiplatelet	55 (19.2)	10 (21.7)	16 (17.2)	26 (19.4)	0.806	0.519	0.675
Beta-blocker	225 (78.4)	38 (82.6)	76 (81.7)	106 (79.6)	0.825	0.898	0.627
Statin	119 (41.5)	15 (32.6)	35 (37.6)	67 (50.3)	0.055	0.561	0.065
ACEi/ARB	241 (84.0)	36 (78.3)	81 (87.1)	117 (87.3)	0.285	0.179	0.962
MRA	64 (22.3)	4 (8.7)	14 (15.1)	45 (33.6)	<0.001	0.293	0.002
Diuretic	116 (40.4)	10 (21.7)	27 (29.0)	78 (58.2)	<0.001	0.360	<0.001

AF, atrial fibrillation; BMI, body mass index; ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; MRA, mineralocorticoid antagonist; NYHA, New York Heart Association class; SOBOE, shortness of breath on exertion; TIA, transient ischaemic attack.

Clinical characteristics

Age and sex distribution of HFmrEF patients fell between HFpEF and HFrEF but no significant differences were seen in cardiovascular risk factors between HFmrEF patients and other groups (Table 1). Groups were comparable for co-morbidities. There were no differences in functional class between the groups. HFmrEF patients reported symptoms of breathlessness in similar proportions to HFpEF patients, and less than HFrEF patients. Diuretic and mineralocorticoid antagonist therapy was lowest in HFpEF and highest in HFrEF.

HFmrEF fell between HFpEF and HFrEF for left- and right-ventricular volumes and mass (Table 2).

Prevalence of occult ischaemic heart disease

Ischaemic LGE was seen in 58 patients (21%) and was more frequent in both HFmrEF and HFrEF (17 and 31%) than in HFpEF (2%), $P < 0.001$. Inducible ischaemia was seen in 20 (7%) overall, most commonly HFmrEF (9.7%) and HFrEF (7.5%) and less often in HFpEF (2.2%), $P = 0.278$. Non-ischaemic LGE was detected in 91 patients (33%) and the prevalence was not significantly different between groups. The presence of occult IHD (defined as either inducible ischaemia or ischaemic

LGE) was 20% in HFmrEF and 33% in HFrEF but only 4% in the HFpEF group ($P < 0.001$ for trend; Table 3).

Tissue characteristics

Native T1 was highest in HFrEF with no significant difference between HFmrEF and HFpEF; HFpEF 1310 ± 34 ms, HFmrEF 1311 ± 32 ms, and HFrEF 1340 ± 45 ms, HFpEF vs. HFmrEF $P = 1.0$, HFmrEF vs. HFrEF $P < 0.001$ (Table 4).

ECV showed the same pattern with highest ECV in HFrEF (implying more interstitial expansion); HFpEF $25.0 \pm 2.7\%$, HFmrEF $24.6 \pm 3.2\%$ and HFrEF $26.3 \pm 3.1\%$, HFpEF vs. HFmrEF $P = 1.0$, HFmrEF vs. HFrEF $P < 0.001$.

Stress MBF showed no difference between HFmrEF and HFpEF, but significantly lower values in HFrEF than the other groups. HFpEF 1.96 ± 0.27 mL/g/min, HFmrEF 1.89 ± 0.62 mL/g/min, and HFrEF 1.51 ± 0.50 mL/g/min, HFpEF vs. HFmrEF $P = 1.0$, HFmrEF vs. HFrEF $P < 0.001$.

Within HF patients, rest MBF was not significantly different between the three groups; HFpEF 0.78 ± 0.27 mL/g/min, HFmrEF 0.71 ± 0.19 mL/g/min, and HFrEF 0.70 ± 0.22 mL/g/min, HFpEF vs. HFmrEF $P = 0.170$, HFmrEF vs. HFrEF $P = 1.0$.

MPR was not different between HFmrEF and HFpEF ($P = 1.0$) but was lower in HFrEF compared with HFmrEF (2.28 ± 0.84 vs. 2.75 ± 0.84 ml/g/min, $P < 0.001$; Table 4).

Table 2 Volumetrics

	All patients 273	HFpEF 46	HFmrEF 93	HFrEF 134	P-value (all HF)	HFpEF:HFmrEF	HFmrEF:HFrEF
LVEF (%)	39.8 ± 12	55.3 ± 4.4	45.2 ± 2.8	28.9 ± 8.0	<0.001	<0.001	<0.001
LVEDVi (mL/m ²)	111 ± 36	85.0 ± 15	101 ± 25	130 ± 39	<0.001	<0.001	<0.001
LV mass indexed (g/m ²)	67.6 ± 19	58.8 ± 15	63.2 ± 18	75.5 ± 18	<0.001	0.236	<0.001
RVEDVi (mL/m ²)	77.8 ± 22	71.3 ± 18	75.7 ± 20	81.9 ± 25	0.011	0.812	0.124
RVEF (%)	49.6 ± 13	56.8 ± 10	52.5 ± 10	44.1 ± 13	<0.001	0.124	<0.001

LVEDVi, indexed left-ventricular end-diastolic volume; RVEDVi, indexed right-ventricular end-diastolic volume; RVEF, right-ventricular ejection fraction.

Table 3 Presence of ischaemic heart disease or late gadolinium enhancement

	All patients 273	HFpEF 46	HFmrEF 93	HFrEF 134	P-value	HFpEF:HFmrEF	HFmrEF:HFrEF
Regional ischaemia	20 (7.3)	1 (2.2)	9 (9.7)	10 (7.5)	0.278	0.107	0.553
Ischaemic LGE	58 (21.2)	1 (2.2)	16 (17.2)	41 (30.6)	<0.001	0.011	0.022
IHD	65 (23.8)	2 (4.3)	19 (20.4)	44 (32.8)	<0.001	0.013	0.040
Non-ischaemic LGE	91 (33.3)	16 (34.8)	25 (26.9)	50 (37.3)	0.254	0.336	0.100

Ischaemic heart disease was seen in a significantly higher proportion of patients with HFmrEF compared with HFpEF, and lower compared with HFrEF.

These findings remained when those with imaging evidence of occult IHD were removed from analysis (see [Supplementary data online, Supplement 2](#)).

Correlation between LVEF and tissue characteristics

When EF was considered as a continuous variable in all patients, there were weak but significant negative correlations between EF and T1 ($r = -0.39$, $P < 0.001$), and EF and ECV ($r = -0.26$, $P < 0.001$).

There was a significant correlation between stress MBF and EF ($r = 0.34$, $P < 0.001$) and MPR and EF ($r = 0.30$, $P < 0.001$). In addition, regression analysis was performed confirming the correlation of EF with T1 (or ECV) and stress MBF (or MPR) independent of age and sex (see [Supplementary data online, Supplement 3](#)).

Discussion

This study has shown that among 273 patients being investigated for the aetiology of HF, those with HFmrEF share most phenotypical characteristics including extent of diffuse fibrosis and microvascular function with HFpEF but have a similar incidence of occult IHD as patients with HFrEF.

Incidence of occult IHD

The incidence of IHD in HFmrEF in unselected HF populations has been reported to range from 41 to 61%,^{6,13} similar to HFrEF and higher than in HFpEF.^{6,7,13–16} Our cohort was more selective and excluded patients with symptoms or history of IHD and the incidence of IHD in all subgroups was therefore lower than in previous studies. However, the overall trend of IHD being more prevalent in HFmrEF than in HFpEF and similar to HFrEF remained. At 20%, the incidence of occult IHD in HFmrEF patients was comparable with that in high risk groups such as older adults¹⁷ and those with Type 2 diabetes¹⁸ with important

potential prognostic implications. Silent ischaemia and infarction are associated with an increased risk of adverse cardiac events.^{17,19–21} The subset of patients with ischaemic HFmrEF may therefore have a worse prognosis than those with no IHD. Within our study, 26% of the HFmrEF population with occult IHD were not receiving either antiplatelet agents or anticoagulation and 60% of patients were not receiving statin therapy, suggesting opportunities for better secondary prevention therapy in this patient group²² although it remains to be shown if such treatment can modulate risk.²³

Diffuse fibrosis

Within our patient group, T1 and ECV in HFmrEF were similar to HFpEF but significantly lower than in HFrEF. Previous studies have examined the significance of ECV in both preserved and reduced LV ejection fraction. In HFpEF, ECV has been shown to be increased when compared with controls, it was a predictor of disease severity such as LV stiffness²⁴ and baseline brain natriuretic peptide,²⁵ and was associated with adverse outcomes including hospitalization for HF and death.^{25,26} CMR registry data have shown that increased ECV is associated with increased risk of HF hospitalization and mortality across the spectrum of ejection fraction, including patients with HFmrEF.²⁷ The evidence for ECV as a prognostic marker in both HFpEF and HFrEF makes it likely that it also has prognostic relevance in HFmrEF and assessment of ECV may help identify subgroups of patients for targeted anti-fibrotic treatment.

Myocardial perfusion

Patients with HFmrEF had reduced stress MBF compared with controls similar to patients with HFpEF, but significantly higher values compared with HFrEF. These findings remained consistent when those with evidence of occult IHD were removed from the analysis.

Microvascular dysfunction leading to chronic hypoperfusion and progressive deterioration in LV function has been suggested as a pathophysiological mechanism for HF.²⁸ The correlation between EF and

Table 4 Parametric data

	All patients 273	HFpEF 46	HFmrEF 93	HFrEF 134	P-value (all HF)	HFpEF:HFmrEF	HFmrEF:HFrEF
Native T1 (ms)	1325 ± 41	1310 ± 34	1311 ± 32	1340 ± 45	<0.001	1.0	<0.001
ECV (%)	25.5 ± 3.1	25.0 ± 2.7	24.6 ± 3.2	26.3 ± 3.1	<0.001	1.0	<0.001
Stress MBF (mL/g/min)	1.72 ± 0.59	1.96 ± 0.61	1.89 ± 0.62	1.51 ± 0.50	<0.001	1.0	<0.001
Rest MBF(mL/g/min)	0.72 ± 0.22	0.78 ± 0.27	0.71 ± 0.19	0.70 ± 0.22	0.070	0.170	1.0
MPR	2.50 ± 0.84	2.62 ± 0.73	2.75 ± 0.84	2.28 ± 0.84	<0.001	1.0	<0.001

Values of native T1, ECV, and stress MBF were not significantly different between HFpEF and HFmrEF. T1 and ECV were significantly higher in HFrEF, and stress MBF significantly lower, when compared with HFmrEF.

stress MBF that we have demonstrated supports this hypothesis, although cannot provide evidence of a causal relationship. Previous studies have shown decreased stress MBF in DCM^{29,30} and severe systolic HF, which has been presumed to be secondary to microvascular disease. In addition, impaired stress MBF is associated with poor prognosis in patients with LV dysfunction, independent of the level of impairment.³⁰ This theory also presents a potential target for medical therapy to slow progression, including in patients with HFmrEF.

We found no correlation between EF and resting MBF. Some previous reports had shown reduced MBF in DCM,^{30,31} suggesting that it may contribute to the development of LV dysfunction through a state of chronic, low-grade hypoperfusion. However, these findings are less consistent between studies, with one PET (positron emission tomography) study showing no difference between controls and DCM groups,²⁸ and another CMR study showing higher resting MBF in DCM compared with controls.²⁹ Resting MBF is subject to multiple factors which can be difficult to control in clinical studies, which may explain the heterogeneity of reported correlations between resting MBF and EF.

Nomenclature

The classification of patients with HF and ejection fraction between 40 and 50% remains inconsistent. ESC guidelines classify this group as a separate entity, suggesting potential unique characteristics, while the AHA guidelines have broadly included this group with HFpEF.³² Within the AHA group, there are two categories, either HFpEF borderline (EF 40–49%) or HFpEF recovered (40–49%) with evidence of previous EF <40%. These two groups would differ significantly in treatment options, with one behaving similarly to HFpEF and unlikely to benefit prognostically from medical therapies, and the other requiring traditional HFrEF treatments to maintain this recovered EF. Distinguishing between these groups without prior imaging evidence is difficult, and tissue characteristics may differ between the two and help inform diagnosis. This distinction points to the potential importance of aetiology rather than EF as a marker for treatment, an area where CMR plays a key role, as demonstrated by the proportion of silent IHD identified in our cohort.

An alternative to the classification of HF according to LVEF is to consider it as a continuous spectrum of disease, defined by phenotype and aetiology.^{33,34} A key argument in support of this approach is that LVEF is not fixed but can fluctuate significantly over time. In a prospective study of patients with a diagnosis of HF, 57% of those initially categorized as HFmrEF changed their EF class within one year, with 24% reducing to HFrEF and 33% increasing in EF to the HFpEF category. Despite the change in LVEF, the underlying disease aetiology in these patients will not have changed. In this context, HFmrEF would be a 'milder' form of HFrEF, demonstrating impaired systolic function, and may

warrant treatment with conventional HF therapies,³⁴ indeed, retrospective analysis from previous trials have suggested that patients with HFmrEF show some benefit from treatment similar to those with HFrEF,^{35–37} leading to the recent change in nomenclature from 'mid-range' to 'mildly reduced'.² Our results demonstrate correlations in T1, ECV, and stress MBF with EF across all patients with HF and thus support the view of HF as a continuum with the most important distinction being its aetiology rather than the degree of LV impairment. CMR may play an important role in the identification of different phenotypes of HFmrEF to optimize their risk stratification.

Limitations

Patients in this study were prospectively recruited from clinical care, where a CMR scan had been requested by the treating clinician. This may have introduced a degree of referral bias where patients not deemed suitable for CMR may have been excluded reducing the proportion of patients with AF, more frail or elderly patients, or those with decompensated HF symptoms. A large proportion of our patients had NYHA Class I symptoms at the time of scanning, potentially because they had been commenced on appropriate medical therapy prior to their scan. This may mean that categorization of HF by EF has changed from what it would have been at first clinical diagnosis, but represents real-world assessment of this patient group. While patients were advised to avoid caffeine prior to their scan, this was not tested for, and previous studies have shown that some patients will still have detectable levels of caffeine at the time of their scan, which may influence the effects of adenosine.

Conclusion

This study provides a detailed description of the HFmrEF phenotype. Patients with HFmrEF share most phenotypic characteristics with HFpEF, including the degree of microvascular impairment and fibrosis, but have a high prevalence of occult IHD similar to HFrEF. Detailed imaging assessment of patients with HFmrEF may be appropriate to optimize secondary prevention. Further work is needed to confirm how the unique phenotype of HFmrEF responds to medical therapy.

Supplementary data

Supplementary data are available at *European Heart Journal – Cardiovascular Imaging* online.

Funding

This research was funded by the British Heart Foundation (RG/16/1/32092) and was supported by the National Institute for Health Research (NIHR),

through the Local Clinical Research Networks and the Leeds Clinical Research Facility.

Conflict of interest: None declared.

Data availability

The data underlying this article will be shared on reasonable request to the corresponding author.

References

1. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS *et al.* 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J* 2016;**37**:2129–200.
2. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M *et al.* 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J* 2021;**42**:3599–726.
3. Lam CSP, Gamble GD, Ling LH, Sim D, Leong KTG, Yeo PSD *et al.* Mortality associated with heart failure with preserved vs. Reduced ejection fraction in a prospective international multi-ethnic cohort study. *Eur Heart J* 2018;**39**:1770–80.
4. Bhatia RS, Tu J V, Lee DS, Austin PC, Fang J, Haouzi A *et al.* Outcome of heart failure with preserved ejection fraction in a population-based study. *NEJM* 2006;**355**:260–9.
5. Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiadu M, Greenberg BH *et al.* Heart failure characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure A report from the OPTIMIZE-HF registry. *JACC* 2007;**50**:768–77.
6. Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo-Leiro MG, Harjola VP *et al.* Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. *Eur J Heart Fail* 2017;**19**:1574–85.
7. Fröhlich H, Rosenfeld N, Täger T, Goode K, Kazmi S, Hole T *et al.* Epidemiology and long-term outcome in outpatients with chronic heart failure in Northwestern Europe. *Heart* 2019;**105**:1252–9.
8. Koh AS, Tay WT, Teng THK, Vedin O, Benson L, Dahlstrom U *et al.* A comprehensive population-based characterization of heart failure with mid-range ejection fraction. *Eur J Heart Fail* 2017;**19**:1624–34.
9. Reddy YNV V, Carter RE, Obokata M, Redfield MM, Borlaug BA. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. *Circulation* 2018;**138**:861–70.
10. Kellman P, Hansen MS, Nielles-Vallespin S, Nickander J, Themudo R, Ugander M *et al.* Myocardial perfusion cardiovascular magnetic resonance: optimized dual sequence and reconstruction for quantification. *J Cardiovasc Magn Reson* 2017;**19**:43.
11. Francis R, Kellman P, Kotecha T, Baggiano A, Norrington K, Martinez-Naharro A *et al.* Prospective comparison of novel dark blood late gadolinium enhancement with conventional bright blood imaging for the detection of scar. *J Cardiovasc Magn Reson* 2017;**19**:91.
12. Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK *et al.* Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the cardiac imaging committee of the council on clinical cardiology of the American Heart Association. *Circulation* 2002;**105**:539–42.
13. Vedin O, Lam CSP, Koh AS, Benson L, Teng THK, Tay WT *et al.* Significance of ischemic heart disease in patients with heart failure and preserved, midrange, and reduced ejection fraction: a nationwide cohort study. *Circ Heart Fail.* 2017;**10**:e003875.
14. Farré N, Lupon J, Roig E, Gonzalez-Costello J, Vila J, Perez S *et al.* Clinical characteristics, one-year change in ejection fraction and long-term outcomes in patients with heart failure with mid-range ejection fraction: a multicentre prospective observational study in Catalonia (Spain). *BMJ Open* 2017;**7**:e018719.
15. Pascual-Figal DA, Ferrero-Gregori A, Gomez-Otero I, Vazquez R, Delgado-Jimenez J, Alvarez-Garcia J *et al.* Mid-range left ventricular ejection fraction: clinical profile and cause of death in ambulatory patients with chronic heart failure. *Int J Cardiol* 2017;**240**:265–70.
16. Webb J, Draper J, Fovargue L, Sieniewicz B, Gould J, Claridge S *et al.* Is heart failure with mid range ejection fraction (HFmrEF) a distinct clinical entity or an overlap group? *J J Clin Heart Vasc* 2018;**21**:1–6.
17. Acharya T, Aspelund T, Jonasson TF, Schelbert EB, Cao JJ, Sathya B *et al.* Association of unrecognized myocardial infarction with long-term outcomes in community-dwelling older adults: the ICELAND MI study. *JAMA Cardiol* 2018;**3**:1101–6.
18. Swoboda PP, McDiarmid AK, Erhayem B, Ripley DP, Dobson LE, Garg P *et al.* Diabetes mellitus, microalbuminuria, and subclinical cardiac disease: identification and monitoring of individuals at risk of heart failure. *J Am Heart Assoc* 2017;**6**:e005539.
19. Kwong RY, Sattar H, Wu H, Vorobiof G, Gandla V, Steel K *et al.* Incidence and prognostic implication of unrecognized myocardial scar characterized by cardiac magnetic resonance in diabetic patients without clinical evidence of myocardial infarction. *Circulation* 2008;**118**:1011–20.
20. Giusca S, Kelle S, Nagel E, Buss SJ, Voss A, Puntmann V *et al.* Differences in the prognostic relevance of myocardial ischaemia and scar by cardiac magnetic resonance in patients with and without diabetes mellitus. *Eur Heart J Cardiovasc Imaging* 2016;**17**:812–20.
21. Zellweger MJ, Hachamovitch R, Kang X, Hayes SW, Friedman JD, Germano G *et al.* Prognostic relevance of symptoms versus objective evidence of coronary artery disease in diabetic patients. *Eur Heart J* 2004;**25**:543–50.
22. Knuuti J, Wijns W, Achenbach S, Agewall S, Barbato E, Bax JJ *et al.* 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. *Eur Heart J* 2020;**41**:407–77.
23. Selvanayagam JB, Hartshorne T, Billot L, Grover S, Hillis GS, Jung W *et al.* Cardiovascular magnetic resonance-GUIDED management of mild to moderate left ventricular systolic dysfunction (CMR GUIDE): study protocol for a randomized controlled trial. *Ann Noninvasive Electrocardiol* 2017;**22**:e12420.
24. Rommel KP, Von Roeder M, Latuscynski K, Oberueck C, Blazek S, Fengler K *et al.* Extracellular volume fraction for characterization of patients with heart failure and preserved ejection fraction. *J Am Coll Cardiol* 2016;**67**:1815–25.
25. Schelbert EB, Fridman Y, Wong TC, Abu Daya H, Piehler KM, Kadakkal A *et al.* Temporal relation between myocardial fibrosis and heart failure with preserved ejection fraction: association with baseline disease severity and subsequent outcome. *JAMA Cardiol* 2017;**2**:995–1006.
26. Kanagala P, Cheng ASH, Singh A, Khan JN, Gulsin GS, Patel P *et al.* Relationship between focal and diffuse fibrosis assessed by CMR and clinical outcomes in heart failure with preserved ejection fraction. *JACC Cardiovasc Imaging* 2019;**12**:2291–301.
27. Schelbert EB, Piehler KM, Zareba KM, Moon JC, Ugander M, Messroghli DR *et al.* Myocardial fibrosis quantified by extracellular volume is associated with subsequent hospitalization for heart failure, death, or both across the spectrum of ejection fraction and heart failure stage. *J Am Heart Assoc* 2015;**4**:e002613.
28. Van Den Heuvel AFM, Van Veldhuisen DJ, Van Der Wall EE, Blanksma PK, Siebelink HMJ, Vaalburg WM *et al.* Regional myocardial blood flow reserve impairment and metabolic changes suggesting myocardial ischemia in patients with idiopathic dilated cardiomyopathy. *J Am Coll Cardiol* 2000;**35**:19–28.
29. Gulati A, Ismail TF, Ali A, Hsu L-Y, Gonçalves C, Ismail NA *et al.* Microvascular dysfunction in dilated cardiomyopathy. *JACC Cardiovasc Imaging* 2019;**12**:1699–708.
30. Neglia D, Michelassi C, Giovanna Trivieri M, Sambucetti G, Giorgetti A, Pratali L *et al.* Prognostic role of myocardial blood flow impairment in idiopathic left ventricular dysfunction. *Circ* 2002;**105**:186–93.
31. Jerosch-Herold M, Sheridan DC, Kushner JD, Nauman D, Burgess D, Dutton D *et al.* Cardiac magnetic resonance imaging of myocardial contrast uptake and blood flow in patients affected with idiopathic or familial dilated cardiomyopathy. *Am J Physiol Heart Circ Physiol* 2008;**295**:1234–42.
32. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH *et al.* 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. *J Am Coll Cardiol* 2013;**62**:e147–239.
33. Triposkiadis F, Butler J, Abboud FM, Armstrong PW, Adamopoulos S, Atherton JJ *et al.* The continuous heart failure spectrum: moving beyond an ejection fraction classification. *Eur Heart J* 2019;**40**:2155–63.
34. Lam CSP, Voors AA, Piotr P, McMurray JVV, Solomon SD. Time to rename the middle child of heart failure: heart failure with mildly reduced ejection fraction. *Eur Heart J* 2020;**41**:2353–5.
35. Lund LH, Claggett B, Liu J, Lam CS, Jhund PS, Rosano GM *et al.* Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. *Eur J Heart Fail* 2018;**20**:1230–9.
36. Abdul-Rahim AH, Shen L, Rush CJ, Jhund PS, Lees KR, McMurray JVV. Effect of digoxin in patients with heart failure and mid-range (borderline) left ventricular ejection fraction. *Eur J Heart Fail* 2018;**20**:1139–45.
37. Cleland JGF, Bunting K V., Flather MD, Altman DG, Holmes J, Coats AJS *et al.* Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. *Eur Heart J* 2018;**39**:26–35.